Hamster Monoclonal to CD79b (mouse), Clone HM79, Isotype IgG2Application FC, IP, WB, ICC Concentration 0.1 mg/ml
- Known as:
- Hamster Monoclonal CD79b (mouse), Clone HM79, Isotype IgG2Application FC, IP, Western Blot, ICC Concentration 0.1 mg/milliliter
- Catalog number:
- 1P-584-C100
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- Hamster Monoclonal CD79b (mouse) Clone HM79 Isotype IgG2Application ICC Concentration 0.1 /
Related genes to: Hamster Monoclonal to CD79b (mouse), Clone HM79, Isotype IgG2Application FC, IP, WB, ICC Concentration 0.1 mg/ml
- Gene:
- CD79B NIH gene
- Name:
- CD79b molecule
- Previous symbol:
- IGB
- Synonyms:
- B29
- Chromosome:
- 17q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-08-04
- Date modifiied:
- 2019-04-23
Related products to: Hamster Monoclonal to CD79b (mouse), Clone HM79, Isotype IgG2Application FC, IP, WB, ICC Concentration 0.1 mg/ml
Related articles to: Hamster Monoclonal to CD79b (mouse), Clone HM79, Isotype IgG2Application FC, IP, WB, ICC Concentration 0.1 mg/ml
- The B cell receptor (BCR) drives the differentiation of naive B cells into activated plasma cells that produce antibodies. The BCR consists of a plasma membrane-bound surface immunoglobulin (sIg) that binds antigens, and two coreceptor subunits CD79A and CD79B. The intracellular domains of CD79A and CD79B initiate immune signaling and endocytosis of the receptor in healthy B cells. In diffuse large B cell lymphoma (DLBCL), an aggressive form of human blood cancer, the activated B cell like (ABC) subtype exhibits constitutive signaling that drives survival and proliferation. Here, in a model of human ABC DLBCL, we determine the localization of BCR components relative to plasma membrane structures using correlative super-resolution light and platinum replica transmission electron microscopy. We find that spontaneous clusters of the surface Immunoglobulin common to ABC lymphoma localize to smooth raised membrane domains. These structures are involved in the endocytosis of large receptor clusters. Surprisingly, activated phosphorylated CD79A (pCD79A) shows little colocalization with clathrin on or off smooth raised membranes. Furthermore, pCD79A spatially segregates away from both the slg and CD79B subunits of the BCR complex. A similar distribution was found for downstream phosphorylated Src family kinases. We propose that a disengagement of pCD79A away from sIg and CD79B allows the receptor to evade down-regulation through endocytosis and maintains signaling at the plasma membrane. This mechanism could drive aberrant signaling and the proliferation of lymphomas leading to disease. - Source: PubMed
Publication date: 2026/09/23
Roberts Aleah DSochacki Kem AStaudt Louis MTaraska Justin W - Primary central nervous system lymphoma (PCNSL) is an uncommon and aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system, including the brain, leptomeninges, spinal cord, and eyes. Although high-dose methotrexate-based induction remains the backbone of first-line therapy, long-term disease control remains challenging, particularly in older or frail patients and in those with relapsed or refractory disease. Recent genomic and multi-omics studies have reshaped the biological understanding of PCNSL by identifying recurrent alterations in MYD88, CD79B, PIM1, PRDM1, CDKN2A/B, HLA-related genes, B2M, CIITA, and immune checkpoint loci, which converge on B-cell receptor/Toll-like receptor signaling, NF-κB activation, immune evasion, and microenvironmental adaptation. These molecular insights have accelerated minimally invasive diagnostics, including targeted mutation assays, multigene circulating tumor DNA profiling, methylation-based approaches, and cytokine analysis in cerebrospinal fluid, vitreous humor, and aqueous humor. Targeted and immune-based therapies, including Bruton tyrosine kinase inhibitors, immunomodulatory agents, immune checkpoint inhibitors, mTOR inhibitors, and CD19-directed chimeric antigen receptor T-cell therapy, have shown variable degrees of clinical activity, particularly in relapsed or refractory disease. However, most evidence remains derived from early-phase trials, single-arm studies, retrospective cohorts, or small series, and treatment selection is not yet routinely biomarker-defined. This review summarizes current advances in molecular taxonomy, pathogenesis, diagnostic work-up, liquid biopsy, prognostic stratification, and therapeutic management of PCNSL, emphasizing how molecular and longitudinal biomarker data may inform individualized treatment and future clinical trial design. - Source: PubMed
Publication date: 2026/07/29
Yan FengShan YongzhiFan XiaotongWang YamingWei PenghuZhao YongruiGuo Yixian - small colony variants (SCVs) represent a persistence-adapted phenotype linked to chronic and recurrent bovine mastitis. Interleukin-10 receptor ⍺ (IL10RA) is a central regulator of anti-inflammatory signalling in the mammary gland, but its role in shaping transcriptional responses to intracellular staphylococcal challenge has not been characterized. - Source: PubMed
Publication date: 2026/09/14
Shandilya Umesh KLiang YanAtalla HebaMallard BonnieKarrow Niel A - Postmenopausal osteoporosis (PMOP) is a skeletal disorder induced by estrogen deficiency. Yishen Gushu formula (YSGSF) has been confirmed to exert positive regulatory effects on bone metabolism, while its underlying mechanism remains to be fully elucidated. In this study, a rat model of PMOP was established via ovariectomy. Following 12 weeks of intervention with YSGSF decoction, its mechanism of action was investigated using Micro-CT, HE staining, RNA sequencing, qRT-PCR, and Western blot. The results demonstrated that YSGSF significantly attenuated bone loss in PMOP rats. A total of 18 differentially expressed genes with expression trends reversed by YSGSF were screened out, and their functions were mainly enriched in B-cell differentiation, immunoglobulin complex, and B-cell receptor (BCR) signaling pathways. The expression levels of , and were downregulated after YSGSF intervention. Collectively, YSGSF may alleviate bone microstructure impairment in PMOP rats by downregulating key genes in the BCR pathway and improving the skeletal immune microenvironment. - Source: PubMed
Publication date: 2026/09/22
Jin BoXiang KelinLi YongjinLi ZhengpengZhang ChiZhang Xiaoyun - The standard first-line R-CHOP regimen achieves cure in only approximately 50% of patients. Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting the B-cell receptor component CD79b; however, evidence regarding its real-world efficacy remains relatively limited. This retrospective study aims to evaluate the clinical efficacy of Pola in combination therapy. - Source: PubMed
Publication date: 2026/09/04
Liu SongshenZhao XiaShi XueXu HongWang WeiSun Lingjie